Richwood Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Richwood Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,375	Closed	-$246K	–	105
2022 Q4	$246K	Hold	2,375	–	–	0.25%	95
2022 Q3	$201K	Sell	2,375 -80	-3%	-$7.12K	0.22%	101
2022 Q2	$203K	Buy	+2,455	New	+$195K	0.2%	104
2022 Q1	–	Sell	-2,455	Closed	-$217K	–	133
2021 Q4	$217K	Buy	+2,455	New	+$203K	0.19%	102

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Richwood Investment Advisors's BMRN Position: Q1 2023 in Review

Richwood Investment Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 2,375 shares — an estimated $246K sold.

Richwood Investment Advisors first reported a position in BMRN in Q4 2021 and held it in 4 quarters. The position peaked at $246K in Q4 2022. 553 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

Richwood Investment Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Richwood Investment Advisors sold 2,375 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $246K.
Richwood Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 4 quarters.
Richwood Investment Advisors's BioMarin Pharmaceuticals position peaked at $246K in Q4 2022.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Richwood Investment Advisors's 13F filing for Q1 2023, filed 19 Apr 2023.